title: Evidence for acute stimulation of fibrinogen production by glucagon in humans.
abstract: Fibrinogen, an acute-phase protein, and glucagon, a stress hormone, are often elevated in many conditions of physical and metabolic stress, including uncontrolled diabetes. However, the possible mechanisms for this association are poorly known. We have studied the acute effects of selective hyperglucagonemia (raised from -200 to -350 pg/ml for 3 h) on fibrinogen fractional secretion rate (FSR) in eight normal subjects during infusion of somatostatin and replacement doses of insulin, glucagon, and growth hormone. Fibrinogen FSR was evaluated by precursor-product relationships using either Phe (n = 8) or Leu (n = 2) tracers. Hyperglucagonemia did not change either plasma Phe or Tyr specific activity. After hyperglucagonemia, fibrinogen FSR increased by approximately 65% (from 12.9 +/- 3.6 to 21.5 +/- 6.1% per day, P < 0.025) using plasma Phe specific activity as the precursor pool. FSR increased by approximately 80% (from 16.6 +/- 4.8 to 29.4 +/- 8.8% per day, P < 0.025) if plasma Phe specific activity was corrected for the ketoisocaproate/Leu enrichment (or specific activity) ratio to obtain an approximate estimate of intrahepatic Phe specific activity. FSR increased by approximately 60% when using plasma Tyr specific activity as precursor pool (n = 8) (P < 0.05), as well as when using the Leu tracer precursor-product relationship (n = 2). In conclusion, selective hyperglucagonemia for approximately 3 h acutely stimulated fibrinogen FSR using a Phe tracer method. Thus, glucagon may be involved in the increase of fibrinogen concentration and FSR observed under stressed or pathologic conditions.
authors.affiliation: Department of Metabolic Diseases, University of Padua, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Tessari
authors.forename: E
authors.initials: E
authors.lastname: Iori
authors.forename: M
authors.initials: M
authors.lastname: Vettore
authors.forename: M
authors.initials: M
authors.lastname: Zanetti
authors.forename: E
authors.initials: E
authors.lastname: Kiwanuka
authors.forename: G
authors.initials: G
authors.lastname: Davanzo
authors.forename: R
authors.initials: R
authors.lastname: Barazzoni
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects; D002250:Carbon Radioisotopes; D005340:Fibrinogen / Q000187:drug effects / Q000378:metabolism*; D005934:Glucagon / Q000008:administration & dosage / Q000097:blood*; D006801:Humans; D007262:Infusions, Intravenous; D007930:Leucine / Q000097:blood / Q000187:drug effects / Q000378:metabolism; D008297:Male; D010649:Phenylalanine / Q000097:blood / Q000187:drug effects / Q000378:metabolism; D014316:Tritium
chemical_list: D001786:Blood Glucose; D002250:Carbon Radioisotopes; D014316:Tritium; D010649:Phenylalanine; D005340:Fibrinogen; D005934:Glucagon; D007930:Leucine